In the present study, we also detected an increase in VEGF immunostaining in the retinas of aged mice, which is consistent with previous studies that reported that anti-VEGF therapy is the standard of care for symptomatic wet AMD and can significantly improve visual acuity (Avery et al., 2006; Rosenfeld et al., 2006). This evidence concerns the gene VEGFA and wet macular degeneration.